News Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 by trophic 14 December, 2021
News Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update by trophic 16 November, 2021
News Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME by trophic 09 November, 2021
